Cue Biopharma
CUE
51 hedge funds and large institutions have $13M invested in Cue Biopharma in 2025 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 5 increasing their positions, 14 reducing their positions, and 4 closing their positions.
100% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 4
9% more capital invested
Capital invested by funds: $11.9M → $13M (+$1.13M)
9% more funds holding
Funds holding: 47 → 51 (+4)
0.47% more ownership
Funds ownership: 23.03% → 23.5% (+0.47%)
64% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 14
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BFM
Boothbay Fund Management
New York
|
+$478K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$85K |
| 3 |
GWMR
GC Wealth Management RIA
Cambridge,
Massachusetts
|
+$78.2K |
| 4 |
Renaissance Technologies
New York
|
+$73.2K |
| 5 |
Squarepoint
New York
|
+$67.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$116K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$73.1K |
| 3 |
Northern Trust
Chicago,
Illinois
|
-$24.7K |
| 4 |
SM
Salzhauer Michael
|
-$10.9K |
| 5 |
LPL Financial
San Diego,
California
|
-$10.2K |
CUE Hedge Fund Activity: Q3 2025 in Review
51 of the 7,642 institutional investors tracked by Wall St. Rank reported a position in Cue Biopharma (CUE) for Q3 2025, worth a combined $13M — up 9.5% from $11.9M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new CUE positions and 4 closed out — a net gain of 4 holders — while 5 added to existing stakes and 14 trimmed.
The largest buyer was Boothbay Fund Management, opening a new position worth an estimated $478K. The largest seller was Vanguard Group, cutting an estimated $116K.
- 51 institutional investors held Cue Biopharma (CUE) as of Q3 2025, up from 47 in Q2 2025.
- Funds reported $13M of Cue Biopharma stock for Q3 2025, up 9.5% quarter-over-quarter.
- 8 funds opened new Cue Biopharma positions in Q3 2025 and 4 closed out, a net change of +4 holders.
- The largest Cue Biopharma buyer in Q3 2025 was Boothbay Fund Management, an estimated $478K added.
- The largest Cue Biopharma seller in Q3 2025 was Vanguard Group, an estimated $116K sold.
Based on aggregated 13F filings for Q3 2025.